Alnylam Pharmaceuticals (ALNY) Return on Capital Employed (2010 - 2026)

Alnylam Pharmaceuticals has reported Return on Capital Employed for 17 years, with the latest figure at 20.34% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed rose 2400.0% year-over-year to 20.34%; the trailing twelve-month figure through Mar 2026 stood at 20.34% (up 2400.0% YoY), and the FY2025 full-year result was 15.99%, up 2220.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 20.34%, up from 14.57% in the prior quarter.
• The five-year high for Return on Capital Employed was 20.34% in Q1 2026, with the low at 31.68% in Q2 2023.
• Historically, Return on Capital Employed has averaged 10.07% across 5 years, with a median of 6.52% in 2024.
• Annual changes were most pronounced in 2024 — Return on Capital Employed surged 3526 bps — and 2025, when it plunged 942 bps.
• Alnylam Pharmaceuticals' Return on Capital Employed stood at 28.31% in 2022, then jumped by 65 bps to 9.84% in 2023, then surged by 41 bps to 5.83% in 2024, then surged by 350 bps to 14.57% in 2025, then jumped by 40 bps to 20.34% in 2026.
• The last three Return on Capital Employed figures came in at 20.34% (Q1 2026), 14.57% (Q4 2025), and 8.39% (Q3 2025), per Business Quant data.